This company listing is no longer active
Probiotec Inkomsten in het verleden
Verleden criteriumcontroles 2/6
Probiotec has been growing earnings at an average annual rate of 24.6%, while the Pharmaceuticals industry saw earnings growing at 47.3% annually. Revenues have been growing at an average rate of 24.6% per year. Probiotec's return on equity is 9.8%, and it has net margins of 3.9%.
Belangrijke informatie
24.6%
Groei van de winst
19.5%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 31.2% |
| Inkomstengroei | 24.6% |
| Rendement op eigen vermogen | 9.8% |
| Nettomarge | 3.9% |
| Laatste winstupdate | 31 Dec 2023 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe Probiotec geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Dec 23 | 221 | 9 | 47 | 0 |
| 30 Sep 23 | 218 | 10 | 45 | 0 |
| 30 Jun 23 | 214 | 11 | 44 | 0 |
| 31 Mar 23 | 209 | 13 | 43 | 0 |
| 31 Dec 22 | 204 | 15 | 41 | 0 |
| 30 Sep 22 | 193 | 14 | 40 | 0 |
| 30 Jun 22 | 182 | 14 | 38 | 0 |
| 31 Dec 21 | 163 | 8 | 34 | 0 |
| 30 Sep 21 | 142 | 7 | 31 | 0 |
| 30 Jun 21 | 121 | 5 | 28 | 0 |
| 31 Dec 20 | 106 | 6 | 24 | 0 |
| 30 Sep 20 | 106 | 6 | 22 | 0 |
| 30 Jun 20 | 107 | 6 | 21 | 0 |
| 31 Mar 20 | 96 | 5 | 19 | 0 |
| 31 Dec 19 | 84 | 4 | 18 | 0 |
| 30 Sep 19 | 79 | 4 | 17 | 0 |
| 30 Jun 19 | 73 | 4 | 17 | 0 |
| 31 Mar 19 | 73 | 4 | 18 | 0 |
| 31 Dec 18 | 72 | 4 | 19 | 0 |
| 30 Sep 18 | 69 | 3 | 19 | 0 |
| 30 Jun 18 | 66 | 3 | 19 | 0 |
| 31 Dec 17 | 60 | 2 | 18 | 0 |
| 30 Sep 17 | 61 | 3 | 18 | 0 |
| 30 Jun 17 | 61 | 3 | 18 | 0 |
| 31 Dec 16 | 63 | 3 | 19 | 0 |
| 30 Sep 16 | 64 | 3 | 20 | 0 |
| 30 Jun 16 | 66 | 2 | 20 | 0 |
| 31 Dec 15 | 64 | 1 | 22 | 0 |
| 30 Sep 15 | 64 | 1 | 22 | 0 |
| 30 Jun 15 | 63 | 0 | 23 | 0 |
| 31 Dec 14 | 65 | -1 | 24 | 0 |
| 30 Sep 14 | 67 | 0 | 24 | 0 |
| 30 Jun 14 | 68 | 1 | 25 | 0 |
| 31 Dec 13 | 65 | 2 | 25 | 0 |
| 30 Sep 13 | 66 | 2 | 26 | 0 |
| 30 Jun 13 | 67 | 1 | 27 | 0 |
Kwaliteitswinsten: PBP has high quality earnings.
Groeiende winstmarge: PBP's current net profit margins (3.9%) are lower than last year (7.2%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: PBP's earnings have grown significantly by 24.6% per year over the past 5 years.
Versnelling van de groei: PBP's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: PBP had negative earnings growth (-41%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (16%).
Rendement op eigen vermogen
Hoge ROE: PBP's Return on Equity (9.8%) is considered low.